MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Syndax Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

12.04 -2.03

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.57

Max

12.27

Belangrijke statistieken

By Trading Economics

Inkomsten

-10M

-94M

Verkoop

-4.8M

7.7M

EPS

-1.1

Winstmarge

-1,226.159

Werknemers

270

EBITDA

-5.3M

-89M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+202% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-188M

1.1B

Vorige openingsprijs

14.07

Vorige sluitingsprijs

12.04

Nieuwssentiment

By Acuity

50%

50%

173 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Syndax Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jul 2024, 12:35 UTC

Belangrijke Marktbewegers

Syndax Pharma Shares Fall Premarket After FDA Extends Revumenib Review

Peer Vergelijking

Prijswijziging

Syndax Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

202% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 36.27 USD  202%

Hoogste 51 USD

Laagste 16 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Syndax Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

12

Buy

1

Hold

0

Sell

Technische score

By Trading Central

N/A / 13.12Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

173 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.